Skip to main content
Erschienen in: European Journal of Pediatrics 8/2008

01.08.2008 | Original Paper

Bronchoalveolar lavage with pulmonary surfactant/dextran mixture improves meconium clearance and lung functions in experimental meconium aspiration syndrome

verfasst von: Andrea Calkovska, Daniela Mokra, Anna Drgova, Ivan Zila, Kamil Javorka

Erschienen in: European Journal of Pediatrics | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Abstract

Surfactant lung lavage is a promising approach in the treatment of meconium aspiration syndrome (MAS). We hypothesise that the enrichment of modified natural surfactant with dextran will enhance meconium clearance from the airspaces during lung lavage and improve lung function in experimental MAS. Human meconium (30 mg/ml; 4 ml/kg) was instilled into the tracheal cannula of anaesthetised and paralysed adult rabbits to induce respiratory failure. The animals were then lavaged with saline (Sal), surfactant without (Surf) and with dextran (Surf+dex). Lung lavage (10 ml/kg in three portions) was performed with diluted surfactant (Curosurf®, 10 mg/ml, 100 mg/kg) without or with dextran (3 mg/mg of surfactant phospholipids) or saline and the animals were conventionally ventilated with 100% O2 for an additional hour. Lung functions were measured prior to and after meconium instillation, and 10, 30 and 60 min after lavage. The recovery of meconium in bronchoalveolar lavage (BAL) fluid was quantified. More meconium solids was recovered in the surfactant-lavaged than in the saline-lavaged groups (Surf: 12.4 ± 3.9% and Surf+dex: 17.5 ± 3.5% vs. Sal: 4.8 ± 1.0%; both P < 0.01). Moreover, more meconium solids was obtained by Curosurf/dextran than by Curosurf-only lavage (P < 0.05). In the Surf group, the values for PaO2/FiO2 were significantly higher than in the controls (at 60 min: 24.5 ± 4.2 kPa vs.9.1 ±  2.2 kPa, P < 0.01). An additional increase in oxygenation was seen in the Surf+dex group (at 60 min: 34.2 ± 8.1 kPa, P vs. Surf group <0.01). The lung-thorax compliance was higher in the Surf+dex group in comparison with the Sal and Surf groups (at 60 min: 9.6 ± 0.9 vs.7.6 ± 1.2, P < 0.01 and 8.0 ± 0.7 ml/kPa/kg, P < 0.05). The enrichment of Curosurf with dextran improves meconium clearance and lung functions in surfactant-lavaged rabbits with meconium aspiration.
Literatur
1.
Zurück zum Zitat Almaas R, Robertson B, Linderholm B, Lundberg E, Saugstad OD, Moen A (2000) Reversal of meconium inhibition of pulmonary surfactant by ferric chloride, copper chloride, and acetic acid. Am J Respir Crit Care Med 162(5):1789–1794PubMed Almaas R, Robertson B, Linderholm B, Lundberg E, Saugstad OD, Moen A (2000) Reversal of meconium inhibition of pulmonary surfactant by ferric chloride, copper chloride, and acetic acid. Am J Respir Crit Care Med 162(5):1789–1794PubMed
2.
Zurück zum Zitat Been JV, Zimmermann LJI (2007) What’s new in surfactant? A clinical view on recent developments in neonatology and paediatrics. Eur J Pediatr 166(9):889–899PubMedCrossRef Been JV, Zimmermann LJI (2007) What’s new in surfactant? A clinical view on recent developments in neonatology and paediatrics. Eur J Pediatr 166(9):889–899PubMedCrossRef
3.
Zurück zum Zitat Calkovska A, Some M, Linderholm B, Johansson J, Curstedt T, Robertson B (2005) Biophysical and physiological properties of porcine surfactant enriched with polymyxin B. Biol Neonate 88:101–108PubMedCrossRef Calkovska A, Some M, Linderholm B, Johansson J, Curstedt T, Robertson B (2005) Biophysical and physiological properties of porcine surfactant enriched with polymyxin B. Biol Neonate 88:101–108PubMedCrossRef
4.
Zurück zum Zitat Cochrane CG, Revak SD, Merritt TA, Schraufstatter IU, Hoch RC, Henderson C, Andreasson S, Takamori H, Oades ZG (1998) Bronchoalveolar lavage with KL4-surfactant in models of meconium aspiration syndrome. Pediatr Res 44:705–715PubMedCrossRef Cochrane CG, Revak SD, Merritt TA, Schraufstatter IU, Hoch RC, Henderson C, Andreasson S, Takamori H, Oades ZG (1998) Bronchoalveolar lavage with KL4-surfactant in models of meconium aspiration syndrome. Pediatr Res 44:705–715PubMedCrossRef
5.
Zurück zum Zitat Cui XG, Tashiro K, Matsumoto H, Tsubokawa Y, Kobayashi T (2003) Aerosolized surfactant and dextran for experimental acute respiratory distress syndrome caused by acidified milk in rats. Acta Anaesthesiol Scand 47(7):853–860PubMedCrossRef Cui XG, Tashiro K, Matsumoto H, Tsubokawa Y, Kobayashi T (2003) Aerosolized surfactant and dextran for experimental acute respiratory distress syndrome caused by acidified milk in rats. Acta Anaesthesiol Scand 47(7):853–860PubMedCrossRef
6.
Zurück zum Zitat Dargaville PA, Morley CJ (2000) Overcoming surfactant inhibition with polymers. Acta Paediatr 89:1397–1400PubMedCrossRef Dargaville PA, Morley CJ (2000) Overcoming surfactant inhibition with polymers. Acta Paediatr 89:1397–1400PubMedCrossRef
7.
Zurück zum Zitat Dargaville PA, Mills JF, Headley BM, Chan Y, Coleman L, Loughnan PM, Morley CJ (2003) Therapeutic lung lavage in the piglet model of meconium aspiration syndrome. Am J Respir Crit Care Med 168(4):456–463PubMedCrossRef Dargaville PA, Mills JF, Headley BM, Chan Y, Coleman L, Loughnan PM, Morley CJ (2003) Therapeutic lung lavage in the piglet model of meconium aspiration syndrome. Am J Respir Crit Care Med 168(4):456–463PubMedCrossRef
8.
Zurück zum Zitat Dargaville PA, Mills JF (2005) Surfactant therapy for meconium aspiration syndrome: current status. Drugs 65:2569–2591PubMedCrossRef Dargaville PA, Mills JF (2005) Surfactant therapy for meconium aspiration syndrome: current status. Drugs 65:2569–2591PubMedCrossRef
9.
Zurück zum Zitat Findlay RD, Taeusch HW, Walther FJ (1996) Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 97:48–52PubMed Findlay RD, Taeusch HW, Walther FJ (1996) Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 97:48–52PubMed
10.
Zurück zum Zitat Greenough A (2000) Expanded use of surfactant replacement therapy. Eur J Pediatr 159(9):635–640PubMedCrossRef Greenough A (2000) Expanded use of surfactant replacement therapy. Eur J Pediatr 159(9):635–640PubMedCrossRef
11.
Zurück zum Zitat Kakinuma R, Shimizu H, Ogawa Y (2002) Effect of meconium on the rate of in vitro subtype conversion of swine pulmonary surfactant. Eur J Pediatr 161(1):31–36PubMed Kakinuma R, Shimizu H, Ogawa Y (2002) Effect of meconium on the rate of in vitro subtype conversion of swine pulmonary surfactant. Eur J Pediatr 161(1):31–36PubMed
12.
Zurück zum Zitat Kobayashi T, Ohta K, Tashiro K, Nishizuka K, Chen W-M, Ohmura S, Yamamoto K (1999) Dextran restores albumin-inhibited surface activity of pulmonary surfactant extract. J Appl Physiol 86(6):1778–1784PubMed Kobayashi T, Ohta K, Tashiro K, Nishizuka K, Chen W-M, Ohmura S, Yamamoto K (1999) Dextran restores albumin-inhibited surface activity of pulmonary surfactant extract. J Appl Physiol 86(6):1778–1784PubMed
13.
Zurück zum Zitat Lam BC, Yeung CY (1999) Surfactant lavage for meconium aspiration syndrome: a pilot study. Pediatrics 103:1014–1018PubMedCrossRef Lam BC, Yeung CY (1999) Surfactant lavage for meconium aspiration syndrome: a pilot study. Pediatrics 103:1014–1018PubMedCrossRef
14.
Zurück zum Zitat Lam BC, Yeung CY, Fu KH, Wong KY, Chan FL, Tsoi NS (2000) Surfactant tracheobronchial lavage for the management of a rabbit model of meconium aspiration syndrome. Biol Neonate 78:129–138PubMedCrossRef Lam BC, Yeung CY, Fu KH, Wong KY, Chan FL, Tsoi NS (2000) Surfactant tracheobronchial lavage for the management of a rabbit model of meconium aspiration syndrome. Biol Neonate 78:129–138PubMedCrossRef
15.
Zurück zum Zitat Lista G, Bianchi S, Castoldi F, Fontana P, Cavigioli F (2006) Bronchoalveolar lavage with diluted porcine surfactant in mechanically ventilated term infants with meconium aspiration syndrome. Clin Drug Investig 26(1):13–19PubMedCrossRef Lista G, Bianchi S, Castoldi F, Fontana P, Cavigioli F (2006) Bronchoalveolar lavage with diluted porcine surfactant in mechanically ventilated term infants with meconium aspiration syndrome. Clin Drug Investig 26(1):13–19PubMedCrossRef
16.
Zurück zum Zitat Lu KW, Taeusch HW, Robertson B, Goerke J, Clements JA (2000) Polymer-surfactant treatment of meconium-induced acute lung injury. Am J Respir Crit Care Med 162:623–628PubMed Lu KW, Taeusch HW, Robertson B, Goerke J, Clements JA (2000) Polymer-surfactant treatment of meconium-induced acute lung injury. Am J Respir Crit Care Med 162:623–628PubMed
17.
Zurück zum Zitat Lu KW, Goerke J, Clements JA, Taeusch HW (2005) Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium injury. Pediatr Res 58:206–210PubMedCrossRef Lu KW, Goerke J, Clements JA, Taeusch HW (2005) Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium injury. Pediatr Res 58:206–210PubMedCrossRef
18.
Zurück zum Zitat Lu KW, Robertson B, Taeusch HW (2005) Dextran or polyethylene glycol added to Curosurf for treatment of meconium lung injury in rats. Biol Neonate 88(1):46–53PubMedCrossRef Lu KW, Robertson B, Taeusch HW (2005) Dextran or polyethylene glycol added to Curosurf for treatment of meconium lung injury in rats. Biol Neonate 88(1):46–53PubMedCrossRef
19.
Zurück zum Zitat Meyuhas D, Nir S, Lichtenberg D (1996) Aggregation of phospholipid vesicles by water-soluble polymers. Biophys J 71:2602–2612PubMedCrossRef Meyuhas D, Nir S, Lichtenberg D (1996) Aggregation of phospholipid vesicles by water-soluble polymers. Biophys J 71:2602–2612PubMedCrossRef
20.
Zurück zum Zitat Moses D, Holm BA, Spitale P, Liu MY, Enhorning G (1991) Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol 164:477–481PubMed Moses D, Holm BA, Spitale P, Liu MY, Enhorning G (1991) Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol 164:477–481PubMed
21.
Zurück zum Zitat Ochs M, Schüttler M, Stichtenoth G, Herting E (2006) Morphological alterations of exogenous surfactant inhibited by meconium can be prevented by dextran. Respir Res 7:86PubMedCrossRef Ochs M, Schüttler M, Stichtenoth G, Herting E (2006) Morphological alterations of exogenous surfactant inhibited by meconium can be prevented by dextran. Respir Res 7:86PubMedCrossRef
22.
Zurück zum Zitat Ohama Y, Ogawa Y (1999) Treatment of meconium aspiration syndrome with surfactant lavage in an experimental rabbit model. Pediatr Pulmonol 28(1):18–23PubMedCrossRef Ohama Y, Ogawa Y (1999) Treatment of meconium aspiration syndrome with surfactant lavage in an experimental rabbit model. Pediatr Pulmonol 28(1):18–23PubMedCrossRef
23.
Zurück zum Zitat Rubin BK, Tomkiewicz RP, Patrinos ME, Easa D (1996) The surface and transport properties of meconium and reconstituted meconium solutions. Pediatr Res 40:834–838PubMedCrossRef Rubin BK, Tomkiewicz RP, Patrinos ME, Easa D (1996) The surface and transport properties of meconium and reconstituted meconium solutions. Pediatr Res 40:834–838PubMedCrossRef
24.
Zurück zum Zitat Sevecova-Mokra D, Calkovska A, Drgova A, Javorka M, Javorka K (2004) Treatment of experimental meconium aspiration syndrome with surfactant lung lavage and conventional vs. asymmetric high-frequency jet ventilation. Pediatr Pulmonol 38:285–291PubMedCrossRef Sevecova-Mokra D, Calkovska A, Drgova A, Javorka M, Javorka K (2004) Treatment of experimental meconium aspiration syndrome with surfactant lung lavage and conventional vs. asymmetric high-frequency jet ventilation. Pediatr Pulmonol 38:285–291PubMedCrossRef
25.
Zurück zum Zitat Stichtenoth G, Jung P, Walter G, Johansson J, Robertson B, Curstedt T, Herting E (2006) Polymyxin B/pulmonary surfactant mixtures have increased resistance to inactivation by meconium and reduce growth of gram-negative bacteria in vitro. Pediatr Res 59:407–411PubMedCrossRef Stichtenoth G, Jung P, Walter G, Johansson J, Robertson B, Curstedt T, Herting E (2006) Polymyxin B/pulmonary surfactant mixtures have increased resistance to inactivation by meconium and reduce growth of gram-negative bacteria in vitro. Pediatr Res 59:407–411PubMedCrossRef
26.
Zurück zum Zitat Sun B, Curstedt T, Robertson B (1993) Surfactant inhibition in experimental meconium aspiration. Acta Paediatr 82(2):182–189PubMedCrossRef Sun B, Curstedt T, Robertson B (1993) Surfactant inhibition in experimental meconium aspiration. Acta Paediatr 82(2):182–189PubMedCrossRef
27.
Zurück zum Zitat Sun B, Curstedt T, Robertson B (1996) Exogenous surfactant improves ventilation efficiency and alveolar expansion in rats with meconium aspiration. Am J Respir Crit Care Med 154:764–770PubMed Sun B, Curstedt T, Robertson B (1996) Exogenous surfactant improves ventilation efficiency and alveolar expansion in rats with meconium aspiration. Am J Respir Crit Care Med 154:764–770PubMed
28.
Zurück zum Zitat Sun B, Curstedt T, Lindgren G, Franzen B, Alaiya AA, Calkovska A, Robertson B (1997) Biophysical and physiological properties of a modified porcine surfactant enriched with surfactant protein A. Eur Resp J 10:1967–1974CrossRef Sun B, Curstedt T, Lindgren G, Franzen B, Alaiya AA, Calkovska A, Robertson B (1997) Biophysical and physiological properties of a modified porcine surfactant enriched with surfactant protein A. Eur Resp J 10:1967–1974CrossRef
29.
Zurück zum Zitat Taeusch HW, Lu KW, Goerke J, Clements JA (1999) Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med 159:1391–1395 Taeusch HW, Lu KW, Goerke J, Clements JA (1999) Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med 159:1391–1395
30.
Zurück zum Zitat Tashiro K, Kobayashi T, Robertson B (2000) Dextran reduces surfactant inhibition by meconium. Acta Paediatr 89:1439–1445PubMedCrossRef Tashiro K, Kobayashi T, Robertson B (2000) Dextran reduces surfactant inhibition by meconium. Acta Paediatr 89:1439–1445PubMedCrossRef
31.
Zurück zum Zitat Tashiro K, Cui X-G, Kobayashi T, Curstedt T, Robertson B (2003) Modified protocols for surfactant therapy in experimental meconium aspiration syndrome. Biol Neonate 83(1):49–56PubMedCrossRef Tashiro K, Cui X-G, Kobayashi T, Curstedt T, Robertson B (2003) Modified protocols for surfactant therapy in experimental meconium aspiration syndrome. Biol Neonate 83(1):49–56PubMedCrossRef
32.
Zurück zum Zitat Weitzner JS, Strassner HT, Rawlins RG, Mack SR, Anderson RA (1990) Objective assessment of meconium content of amniotic fluid. Obstet Gynecol 76:1143–1144PubMed Weitzner JS, Strassner HT, Rawlins RG, Mack SR, Anderson RA (1990) Objective assessment of meconium content of amniotic fluid. Obstet Gynecol 76:1143–1144PubMed
33.
Zurück zum Zitat Wiswell TE, Knight GR, Finer NN, Donn SM, Desai H, Walsh WF, Sekar KC, Bernstein G, Keszler M, Visser VE, Merritt TA, Mannino FL, Mastrioianni L, Marcy B, Revak SD, Tsai H, Cochrane CG (2002) A multicenter, randomized, controlled trial comparing Surfaxin (lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 109:1081–1087PubMedCrossRef Wiswell TE, Knight GR, Finer NN, Donn SM, Desai H, Walsh WF, Sekar KC, Bernstein G, Keszler M, Visser VE, Merritt TA, Mannino FL, Mastrioianni L, Marcy B, Revak SD, Tsai H, Cochrane CG (2002) A multicenter, randomized, controlled trial comparing Surfaxin (lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 109:1081–1087PubMedCrossRef
Metadaten
Titel
Bronchoalveolar lavage with pulmonary surfactant/dextran mixture improves meconium clearance and lung functions in experimental meconium aspiration syndrome
verfasst von
Andrea Calkovska
Daniela Mokra
Anna Drgova
Ivan Zila
Kamil Javorka
Publikationsdatum
01.08.2008
Verlag
Springer-Verlag
Erschienen in
European Journal of Pediatrics / Ausgabe 8/2008
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-007-0596-7

Weitere Artikel der Ausgabe 8/2008

European Journal of Pediatrics 8/2008 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.